Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bendamustine plus prednisone, vinblastine, and doxorubicin in older classical Hodgkin lymphoma patients
2014-001002-17Phase 2Completed
- Sponsor
- LYSARC
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine in classical Hodgkin lymphoma (cHL), sponsored by LYSARC. Primary endpoint: Complete Metabolic Response rate. Started Jun 2015; status: completed.
02
Drugs
bendamustine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2014-001002-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001002-17.